Coagulation and inflammation in acute lung injury

被引:0
作者
Welty-Wolf, KE
Carraway, MS
Ortel, TL
Piantadosi, CA
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Durham, NC 27710 USA
[2] Duke Univ, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[3] Duke Univ, Dept Med, Div Hematol, Durham, NC 27710 USA
[4] Durham VA Med Ctr, Durham, England
关键词
acute respiratory distress syndrome; sepsis; thromboplastin;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The acute respiratory distress syndrome (ARDS) is a severe lung injury in patients with sepsis and other acute inflammatory insults, which is characterized by fibrin deposition in the pulmonary parenchyma, vasculature, and airspaces. Recent evidence suggests that progressive ARDS is closely linked to activation of inflammation and coagulation. Coagulation becomes activated by circulating endotoxin or bacteria, and a procoagulant state develops in the vascular and the alveolar compartments of the lung. This state is Tissue Factor (TF)-dependent and associated with increased elaboration of inflammatory cytokines. A similar procoagulant state is found in bronchoalveolar lavage of patients with ARDS, suggesting that extravascular coagulation contributes to lung inflammation. TF and other coagulation proteins, including Factor Xa, thrombin, and fibrin, also contribute to the pathogenesis of acute lung injury through mufti-level interactions with inflammatory effectors, in which these proteins coordinately act as regulators of tissue injury responses. Each coagulation protein has direct and independent effects on inflammatory events that influences lung injury through changes in cytokine elaboration, inflammatory cell migration and activation, surfactant function, and repair mechanisms. New interventional strategies directed at procoagulant activity highlight the importance of the coagulation system to acute lung injury and suggest that blockade of initiation of coagulation may have therapeutic benefit in patients with ARDS.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 110 条
[1]   Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor [J].
Abe, K ;
Shoji, M ;
Chen, J ;
Bierhaus, A ;
Danave, I ;
Micko, C ;
Casper, K ;
Dillehay, DL ;
Nawroth, PP ;
Rickles, FR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (15) :8663-8668
[2]   Why immunomodulatory therapies have not worked in sepsis [J].
Abraham, E .
INTENSIVE CARE MEDICINE, 1999, 25 (06) :556-566
[3]   Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis - Question and answer session after scientific review [J].
Vincent, JL ;
Abraham, E ;
Esmon, C ;
Hack, CE .
CRITICAL CARE MEDICINE, 2000, 28 (09) :S33-S33
[4]   INFLAMMATORY CELL PARTICIPATION IN COAGULATION [J].
ALTIERI, DC .
SEMINARS IN CELL BIOLOGY, 1995, 6 (05) :269-274
[5]  
ASHBAUGH DG, 1967, LANCET, V2, P319
[6]  
BACHOFEN M, 1982, CLIN CHEST MED, V3, P35
[7]  
Bajaj MS, 1997, THROMB HAEMOSTASIS, V78, P471
[8]   Therapeutic use of antithrombin concentrate in sepsis [J].
Balk, R ;
Emerson, T ;
Fourrier, F ;
Kruse, JA ;
Mammen, EF ;
Schuster, HP ;
Vinazzer, H .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 (02) :183-194
[9]   Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury [J].
Barazzone, C ;
Belin, D ;
Piguet, PF ;
Vassalli, JD ;
Sappino, AP .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12) :2666-2673